Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and effectively reduces pressure and volume in the heart. This is the first study targeting the SVC as a therapeutic area for heart failure patients to reduce cardiac filling pressures without reducing cardiac output or systemic blood pressure. Data was presented as late-breaking clinical research at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans and outcomes in patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS). Results showed more than one-third of the patients’ initial treatment plans changed after FFR. The findings from the global registry were presented as late-breaking clinical research at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical candidate, firibastat, in patients with heart failure after acute myocardial infarction (AMI). Firibastat is a first-in-class brain aminopeptidase A inhibitor, being developed for the treatment of resistant hypertension and heart failure.

June 14, 2019 – An expert consensus statement provides recommendations for optimizing the financial operations of the cardiovascular catheterization laboratory (CCL) while providing cutting-edge patient care. It is intended for any physician, administrator, or CCL staff member who desires a fundamental understanding of finances and economics of CCLs in the U.S.